RT Book, Section
A1 Narla, Goutham
A2 Murray, Michael F.
A2 Babyatsky, Mark W.
A2 Giovanni, Monica A.
A2 Alkuraya, Fowzan S.
A2 Stewart, Douglas R.
SR Print(0)
ID 1102700799
T1 Prostate Cancer
T2 Clinical Genomics: Practical Applications in Adult Patient Care
YR 2014
FD 2014
PB McGraw-Hill Education
PP New York, NY
SN 9780071622448
LK accessmedicine.mhmedical.com/content.aspx?aid=1102700799
RD 2024/04/18
AB Disease  summary:Prostate  cancer  is  the  second  most  fatal  cancer  for  American  men.  It  is  the  most  common  male  noncutaneous  cancer  in  developing  countries,  and  a  leading  cause  of  death  for  men  60  years  or  older.Age,  African  ancestry,  and  a  positive  family  history  are  risk  factors  for  disease  development  (Table  48-1).Recent  evidence  suggests  that  approximately  10%  of  prostate  cancers  are  hereditary.Adenocarcinoma,  cancer  of  glandular  epithelial  cells,  is  the  most  commonly  diagnosed  form.Early  diagnosis  significantly  improves  treatment  response  and  overall  survival  and  is  based  on  both  biochemical  studies  using  prostate-specific  antigen  (PSA)  levels  in  patients  and  subsequent  biopsies  with  Gleason  scoring.Treatment  modalities  for  prostate  cancer  include  hormone-based  approaches,  radiation,  cytotoxic  chemotherapy,  and  radical  prostatectomy.  Despite  proper  treatment  many  prostate  cancer  patients  experience  recurrence  and  will  eventually  develop  aggressive  metastatic  prostate  cancer,  even  when  presenting  initially  with  localized  or  indolent  disease.  No  consistent  biomarkers  yet  exist  to  distinguish  between  indolent  and  aggressive  forms.  Prostate  cancer’s  genetic  heterogeneity  and  complexity  have  hindered  the  elucidation  and  exploitation  of  the  pathways  driving  pathogenesis  and  disease  progression.